Literature DB >> 20072667

Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development.

Yunda Huang1, Peter B Gilbert, David C Montefiori, Steve G Self.   

Abstract

Both the magnitude and breadth of neutralization against multiple strains of virus are main endpoints for comparing antibody-based HIV-1 vaccine candidates in Phase I and II trials, and are key markers to be evaluated in vaccine efficacy trials as immune correlates of protection against HIV-1 infection. More generally, consideration of both magnitude and breadth is encountered when there is interest in comparing quantitative multivariate response data between groups. In this paper, we discuss two approaches to simultaneously evaluating the magnitude and breadth of a multivariate response. We suggest methods for the summarization and group comparison of multivariate response data that are subject to left and/or right censoring. Applications to data from a phase III clinical trial (Vax004) are discussed. Simulation-based sample size calculations and power analyses of the described methods also are presented.

Entities:  

Year:  2009        PMID: 20072667      PMCID: PMC2805400          DOI: 10.1198/sbr.2009.0008

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  8 in total

1.  Sample size estimation for GEE method for comparing slopes in repeated measurements data.

Authors:  Sin-Ho Jung; Chul Ahn
Journal:  Stat Med       Date:  2003-04-30       Impact factor: 2.373

2.  Generalized log-rank test for mixed interval-censored failure time data.

Authors:  Qiang Zhao; Jianguo Sun
Journal:  Stat Med       Date:  2004-05-30       Impact factor: 2.373

3.  Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Authors:  John R Mascola; Patricia D'Souza; Peter Gilbert; Beatrice H Hahn; Nancy L Haigwood; Lynn Morris; Christos J Petropoulos; Victoria R Polonis; Marcella Sarzotti; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Sample size calculations for studies with correlated observations.

Authors:  G Liu; K Y Liang
Journal:  Biometrics       Date:  1997-09       Impact factor: 2.571

5.  Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Authors:  Peter B Gilbert; Michael L Peterson; Dean Follmann; Michael G Hudgens; Donald P Francis; Marc Gurwith; William L Heyward; David V Jobes; Vladimir Popovic; Steven G Self; Faruk Sinangil; Donald Burke; Phillip W Berman
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

6.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

7.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

  8 in total
  28 in total

1.  Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Allan deCamp; Peter Hraber; Robert T Bailer; Michael S Seaman; Christina Ochsenbauer; John Kappes; Raphael Gottardo; Paul Edlefsen; Steve Self; Haili Tang; Kelli Greene; Hongmei Gao; Xiaoju Daniell; Marcella Sarzotti-Kelsoe; Miroslaw K Gorny; Susan Zolla-Pazner; Celia C LaBranche; John R Mascola; Bette T Korber; David C Montefiori
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

Review 2.  Recent developments in clinical trial designs for HIV vaccine research.

Authors:  Laura Richert; Edouard Lhomme; Catherine Fagard; Yves Lévy; Geneviève Chêne; Rodolphe Thiébaut
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Authors:  Karen V Kibler; Benedikt Asbach; Beatriz Perdiguero; Juan García-Arriaza; Nicole L Yates; Robert Parks; Sherry Stanfield-Oakley; Guido Ferrari; David C Montefiori; Georgia D Tomaras; Mario Roederer; Kathryn E Foulds; Donald N Forthal; Michael S Seaman; Steve Self; Raphael Gottardo; Sanjay Phogat; James Tartaglia; Susan Barnett; Anthony D Cristillo; Deborah Weiss; Lindsey Galmin; Song Ding; Jonathan L Heeney; Mariano Esteban; Ralf Wagner; Giuseppe Pantaleo; Bertram L Jacobs
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

4.  HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

Authors:  Pierre-Alexandre Bart; Yunda Huang; Shelly T Karuna; Samuel Chappuis; Julien Gaillard; Nidhi Kochar; Xiaoying Shen; Mary A Allen; Song Ding; John Hural; Hua-Xin Liao; Barton F Haynes; Barney S Graham; Peter B Gilbert; M Juliana McElrath; David C Montefiori; Georgia D Tomaras; Giuseppe Pantaleo; Nicole Frahm
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

5.  A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities.

Authors:  Jeffrey R Schneider; Xiaoying Shen; Chiara Orlandi; Tinashe Nyanhete; Sheetal Sawant; Ann M Carias; Archer D Smith; Neil L Kelleher; Ronald S Veazey; George K Lewis; Georgia D Tomaras; Thomas J Hope
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

6.  Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.

Authors:  Glenda E Gray; Ying Huang; Nicole Grunenberg; Fatima Laher; Surita Roux; Erica Andersen-Nissen; Stephen C De Rosa; Britta Flach; April K Randhawa; Ryan Jensen; Edith M Swann; Linda-Gail Bekker; Craig Innes; Erica Lazarus; Lynn Morris; Nonhlanhla N Mkhize; Guido Ferrari; David C Montefiori; Xiaoying Shen; Sheetal Sawant; Nicole Yates; John Hural; Abby Isaacs; Sanjay Phogat; Carlos A DiazGranados; Carter Lee; Faruk Sinangil; Nelson L Michael; Merlin L Robb; James G Kublin; Peter B Gilbert; M Juliana McElrath; Georgia D Tomaras; Lawrence Corey
Journal:  Sci Transl Med       Date:  2019-09-18       Impact factor: 17.956

7.  Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.

Authors:  Susan Zolla-Pazner; X-P Kong; Xunqing Jiang; Timothy Cardozo; Arthur Nádas; Sandra Cohen; Maxim Totrov; Michael S Seaman; Shixia Wang; Shan Lu
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

8.  Robust antibody and cellular responses induced by DNA-only vaccination for HIV.

Authors:  Stephen C De Rosa; Srilatha Edupuganti; Yunda Huang; Xue Han; Marnie Elizaga; Edith Swann; Laura Polakowski; Spyros A Kalams; Michael C Keefer; Janine Maenza; Yiwen Lu; Megan C Wise; Jian Yan; Matthew P Morrow; Amir S Khan; Jean D Boyer; Laurent Humeau; Scott White; Michael Pensiero; Niranjan Y Sardesai; Mark L Bagarazzi; David B Weiner; Guido Ferrari; Georgia D Tomaras; David C Montefiori; Lawrence Corey; M Juliana McElrath
Journal:  JCI Insight       Date:  2020-07-09

9.  Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.

Authors:  Peter Gilbert; Maggie Wang; Terri Wrin; Chris Petropoulos; Marc Gurwith; Faruk Sinangil; Patricia D'Souza; Isaac R Rodriguez-Chavez; Allan DeCamp; Mike Giganti; Phillip W Berman; Steve G Self; David C Montefiori
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

10.  Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.

Authors:  Hannes Uchtenhagen; Torben Schiffner; Emma Bowles; Leo Heyndrickx; Celia LaBranche; Steven E Applequist; Marianne Jansson; Thushan De Silva; Jaap Willem Back; Adnane Achour; Gabriella Scarlatti; Anders Fomsgaard; David Montefiori; Guillaume Stewart-Jones; Anna-Lena Spetz
Journal:  J Immunol       Date:  2014-05-14       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.